4th May 2022
Radiotracer approved for brain tumour diagnostics
The Federal Joint Committee (G-BA) has approved the radiopharmaceutical [18F]-fluoroethyltyrosine (FET) for the diagnosis of brain tumours in the context of outpatient specialist care. This is the first time that an examination procedure developed at the Forschungszentrum Jülich has been approved for medical use in Germany and reimbursed by the health insurance funds.